# OnCo record nct06545955 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06545955/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06545955", "NCT06545955" ;
  schema:name "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer"@en ;
  schema:alternateName "ABLE-22"@en ;
  schema:description "A phase 3 trial of Nadofaragene firadenovec, Gemcitabine, Docetaxel and Pembrolizumab in bladder & urothelial cancer, run by Ferring Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06545955/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06545955> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-10-01" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bcg-and-intravesical-therapy/> ;
  onco:drugs <https://onco.cc/drugs/nadofaragene-firadenovec/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/ferring/> .